CN106310108A - Medicinal composition for treating fatty liver - Google Patents
Medicinal composition for treating fatty liver Download PDFInfo
- Publication number
- CN106310108A CN106310108A CN201510353665.5A CN201510353665A CN106310108A CN 106310108 A CN106310108 A CN 106310108A CN 201510353665 A CN201510353665 A CN 201510353665A CN 106310108 A CN106310108 A CN 106310108A
- Authority
- CN
- China
- Prior art keywords
- fatty liver
- fructus crataegi
- curcumae longae
- rhizoma curcumae
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides a traditional Chinese medicinal composition for treating fatty liver including alcoholic fatty liver and non-alcoholic fatty liver. The traditional Chinese medicinal composition is prepared by adopting radix salviae miltiorrhizae, radix curcumae longae, fructus crataegi and Chinese wolfberry fruits as raw medicinal materials. The traditional Chinese medicinal composition has the functions of promoting blood circulation to dispel blood stasis, promoting the circulation of qi to dissipate blood stasis, and reducing blood fat.
Description
Technical field
The present invention provides a kind of Chinese medicine composition treating fatty liver, belongs to technical field of traditional Chinese medicine.
Background technology
Fatty liver, refers to due to the pathological changes that athero in the hepatocyte that a variety of causes causes is too much.The just serious prestige of fatty liver disease
The health of side of body compatriots, becomes the second largest hepatopathy being only second to viral hepatitis, has been acknowledged as the common cause of disguised liver cirrhosis.
Fatty liver is a kind of common clinical picture, rather than a kind of independent disease.The lighter is asymptomatic in its clinical manifestation, and the severe one state of an illness is fierce
Suddenly.It is said that in general, fatty liver belongs to reversibility disease, early diagnosis is also treated in time and often can be recovered normal.
Common fatty liver type has:
Alcoholic fatty liver: long-term alcoholic needle biopsy of liver, 75%～95% has fatty infiltration.Somebody observes, and every day drinks
Wine more than 80～160 grams then alcoholic fatty liver incidence rate increase by 5～25 times.
Non-alcohol fatty liver (NAFLD) refer to except ethanol and other clear and definite hepatocyte lactone damaged caused by liver factor
Fat over-deposit is the clinical pathology syndrome of principal character, acquired generation closely-related with insulin resistant and genetic predisposition
Thank to irritability hepatic injury.Hard including simple fatty liver (SFL), non-alcoholic stellato-hepatitis (NASH) and relevant liver thereof
Change.Along with the fat and fashion trend of associated metabolic syndrome globalization, non-alcohol fatty liver has become America and Europe etc.
Developed country and the Important cause of disease of China's areas of well-being chronic hepatopathy, average adult's NAFLD prevalence 10%～30%, wherein
10%～20% is NASH, the latter in 10 years liver cirrhosis incidence rate be up to 25%.Non-alcohol fatty liver is except can directly lead
Cause, outside decompensated liver cirrhosis, hepatocarcinoma and liver transplantation recurrence, also to affect the progress of other chronic hepatopathys, and participate in 2 types
Diabetes and atherosclerotic morbidity.Metabolism syndrome associated malignancies, arteriosclerotic cardiovascular and cerebrovascular disease and liver
It is hardened to affect the key factor of patients with nonalcoholic fatty liver disease quality of life and life expectancy.To this end, non-alcoholic fatty
Property hepatopathy is the new challenge in contemporary medical science field, and the harm of human health will constantly be increased by non-alcohol fatty liver at no distant date
Add.
Summary of the invention
The present invention provides one to treat fatty liver, including alcoholic fatty liver and the Chinese medicine composition of non-alcoholic fatty liver disease.
Chinese medicine composition of the present invention includes Radix Salviae Miltiorrhizae 10-15g, Rhizoma Curcumae Longae 3-9g, Fructus Crataegi 9-12g, Fructus Lycii 9-12g.Chinese medicine of the present invention
Compositions has blood circulation promoting and blood stasis dispelling, circulation of qi promoting dissipating blood stasis, the effect of blood fat reducing, has reduction serum total cholesterol, triglyceride, low close
The effect of degree lipoprotein cholesterol, is used for treating fatty liver, including alcoholic fatty liver and non-alcoholic fatty liver disease.
In Chinese medicine composition of the present invention, the effect of each component is as follows:
Radix Salviae Miltiorrhizae: bitter in the mouth, is slightly cold.Blood circulation promoting and blood stasis dispelling, inducing menstruation to relieve menalgia, clear away heart-fire relieving restlessness, removing heat from blood eliminating carbuncle.For obstruction of qi in the chest and cardialgia, gastral cavity abdomen
Hypochondriac pain, the accumulation of abdominal mass abdominal mass, pyretic arthralgia pain, dysphoria and insomnia, menoxenia, dysmenorrhea amenorrhea, skin infection swells and ache.Radix Salviae Miltiorrhizae can increase liver
Reduced glutathion level in mitochondrion, reduces Serum ALT levels.Liver plasma membrane system can well be protected by Radix Salviae Miltiorrhizae, improves
Its stability.Radix Salviae Miltiorrhizae has good protective effect to alcoholic liver injury.
Rhizoma Curcumae Longae: acrid in the mouth is bitter, temperature.Energy circulation of qi promoting removing blood stasis with potent drugs, inducing menstruation to relieve menalgia.Cure mainly chest and abdomen swelling and pain, take on arm arthralgia pain, pained unbearably, produce
Rear blood pain, skin ulcer tinea onset, menoxenia, amenorrhea, traumatic injury.Rhizoma Curcumae Longae can significantly reduce the blood of the mice that high lipid food is fed
The cholesterol of cleer and peaceful liver and content of triglyceride.
Fructus Crataegi: promoting digestion and invigorating the stomach, circulation of qi promoting dissipating blood stasis.There is the effects such as blood fat reducing, blood pressure, heart tonifying, arrhythmia, be also simultaneously
Spleen benefiting and stimulating the appetite, relieving dyspepsia, the good medicine of phlegm reduction of blood circulation promoting, the disease such as, hernia, blood stasis full to chest and diaphragm spleen, amenorrhea has good curative effect.
Fructus Crataegi flavone can significantly reduce the serum total cholesterol of Experimental Hyperlipemia animal, low-density lipoprotein cholesterol and apolipoprotein
Concentration, notable high density lipoprotein increasing one cholesterol and apolipoprotein concentration, but little on triglyceride impact.Fructus Crataegi fall blood
Fat effect is the synthesis by suppressing hepatic cholesterol, promotes that plasma cholesterol is taken the photograph people and played effect for reducing blood fat by liver.Mountain
Short, bristly hair or beard flavone also can reduce the danger that atherosclerosis occurs, and plays the atherosis effect that development occurs of prevention of arterial.
Fructus Lycii: sweet is flat.Nourishing the liver and kidney, replenishing vital essence to improve eyesight.Moisten for the sweet flat matter of syndrome of yin deficiency of liver and kidney this product, flat invigorating the liver and kidney, have
Strengthening by means of tonics effect, all cards of all hepatic and renal YIN deficiency all can be applied.The lipotropy of Fructus Lycii:
Glycine betaine in rat Long-term Oral fruit, can raise the phospholipid level in blood and liver；Taking glycine betaine in advance or simultaneously can
Phospholipid, the attenuating of total cholesterol level in the rats'liver that antagonism carbon tetrachloride causes, and increase；To, alkaline phosphatase lipase,
Acetylcholine esterase etc. all have improvement result.
Aforementioned four component has the effect of Synergistic, jointly plays blood circulation promoting and blood stasis dispelling, circulation of qi promoting dissipating blood stasis, the effect of blood fat reducing, tool
There are reduction serum total cholesterol, triglyceride, the effect of low-density lipoprotein cholesterol, are used for treating fatty liver, including ethanol
Property fatty liver and non-alcoholic fatty liver disease.
The preparation method of Chinese medicine composition of the present invention is as follows:
Taking Radix Salviae Miltiorrhizae, Rhizoma Curcumae Longae, Fructus Crataegi, Fructus Lycii, add 2-5 times of soak by water 1-3 hour, filter, filtrate is condensed into thick paste；
Or, take Radix Salviae Miltiorrhizae, Rhizoma Curcumae Longae, Fructus Crataegi, Fructus Lycii, add 2-5 times of 60-90% alcohol heating reflux 1-2 hour, reflux, extract,
1-2 time, filtering, filtrate is condensed into thick paste.
Above-mentioned thick paste adds adjuvant, makes pill or tablet.Described adjuvant includes one or more in following adjuvant: starch,
Lactose, pregelatinized Starch, microcrystalline Cellulose, refined honey etc..
Or, above-mentioned thick paste is further dried, and pulverizes, makes pill, tablet or capsule.
The ratio of each component of the present invention is (every consumption per day): Radix Salviae Miltiorrhizae 10-15g, Rhizoma Curcumae Longae 3-9g, Fructus Crataegi 9-12g, Fructus Lycii 9-12g.
More preferably (every consumption per day): Radix Salviae Miltiorrhizae 10g, Rhizoma Curcumae Longae 3g, Fructus Crataegi 9g, Fructus Lycii 9g.Or it is more preferably (every
Consumption per day): Radix Salviae Miltiorrhizae 10g, Rhizoma Curcumae Longae 6g, Fructus Crataegi 6g, Fructus Lycii 6g.
Four components of important composition of the present invention have the effect of Synergistic, jointly play blood circulation promoting and blood stasis dispelling, circulation of qi promoting dissipating blood stasis, fall
The effect of blood fat, has reduction serum total cholesterol, triglyceride, the effect of low-density lipoprotein cholesterol, it is adaptable to treatment
Fatty liver, including alcoholic fatty liver and non-alcoholic fatty liver disease.
Detailed description of the invention
The invention will be further described by the following examples, but this is not limitation of the present invention, those skilled in the art
According to the basic thought of the present invention, various modifications may be made or improves, but without departing from the basic thought of the present invention, all
Within the scope of the present invention.
Embodiment 1:
Radix Salviae Miltiorrhizae 10g, Rhizoma Curcumae Longae 6g, Fructus Crataegi 6g, Fructus Lycii 6g add 3 times of 75% alcohol heating reflux 1.5 hours, reflux, extract, 2
Secondary, merging filtrate, filter, filtrate reduced in volume becomes thick paste, is further dried, and grinds to form fine powder, encapsulated.
Embodiment 2:
Radix Salviae Miltiorrhizae 10g, Fructus Crataegi 9g, Fructus Lycii 9g add 3 times of soak by water 2 hours, filter, and filtrate is condensed into thick paste；Rhizoma Curcumae Longae 3g
It is ground into fine powder and crosses 100 mesh sieves；Mix above-mentioned thick paste and fine powder, add appropriate pregelatinized Starch, refined honey, mould preparation method and prepare pill.
Embodiment 3:
Radix Salviae Miltiorrhizae 10g, Rhizoma Curcumae Longae 3g, Fructus Crataegi 9g, Fructus Lycii 9g add 3 times of soak by water 2 hours, filter, and filtrate is condensed into thick paste；
Appropriate pregelatinized Starch, refined honey, mould preparation method and prepare pill.
Pharmacodynamic experiment:
Experiment material:
Animal: SD male rat 36, body weight 160 ± 10g.
Medicine: test medicine: medicine group of the present invention: embodiment 1 medicine, is prepared as the mixed of 1g crude drug/mL concentration with drinking water
Suspension；Positive control drug: rosiglitazone, is prepared as the suspension of 0.067g/L with drinking water.
Experimental technique:
9 rat not modelings of Normal group.
Model group, 27 the rat modelings of administration group, modeling method: high lipid food (10% Adeps Sus domestica, 2% cholesterol, 88% basis
Feedstuff) raise 8 weeks.
Modeling the 4th week, 27 rats are randomly divided into 3 groups: model group, of the present invention group, positive control drug group, often group 9.
Medicine group dose every day of the present invention is 650mg crude drug/100g Mus weight.
The drinking water of normal group, model group then gavage respective amount.
Serum alanine aminotransferase (ALT) determination of activity: reitman-frankel method.Hepatic tissue triacylglycerol (TG) assay: with reference to Lee
Red Hill etc. damp eliminating Huayu prescription improves the mechanism of Rats with Fatty Liver fatty acids metabolism. and Journal of Traditional Chinese Medicine .2010.51 (3): 262-264.
Table 1: each group liver tissues of rats triacylglycerol (TG) content and serum alanine aminotransferase (ALT) activity:
| Group | Hepatic tissue TG/mg/g | ALT/U/L |
| Normal group | 11.37±2.08 | 22.19±15.63 |
| Model group | 96.21±9.30 | 42.35±13.81 |
| Of the present invention group | 38.79±7.50 | 26.94±4.07 |
| Rosiglitazone group | 53.44±10.65 | 31.97±9.01 |
Of the present invention group is compared p ＜ 0.01 with model group, compares p ＜ 0.05 with positive control drug group.
Conclusion: the present invention has significantly prevention and the effect for the treatment of fatty liver.
Claims (5)
1. treat a pharmaceutical composition for fatty liver, be made up of the Chinese crude drug of following weight ratio example: Radix Salviae Miltiorrhizae 10-15g, Rhizoma Curcumae Longae 3-9g,
Fructus Crataegi 9-12g, Fructus Lycii 9-12g.
Pharmaceutical composition the most according to claim 1, is made up of the Chinese crude drug of following weight ratio example: Radix Salviae Miltiorrhizae 10g, Rhizoma Curcumae Longae 3g,
Fructus Crataegi 9g, Fructus Lycii 9g.
Pharmaceutical composition the most according to claim 1, is made up of the Chinese crude drug of following weight ratio example: Radix Salviae Miltiorrhizae 10g, Rhizoma Curcumae Longae 6g,
Fructus Crataegi 6g, Fructus Lycii 6g.
4. the preparation method of the pharmaceutical composition described in claim 1: take Rhizoma Curcumae Longae, Fructus Crataegi, Fructus Crataegi, Fructus Lycii, adds 2-5 times of decocting
Boiling 1-3 hour, filter, filtrate is condensed into thick paste；Above-mentioned thick paste adds adjuvant, makes pill or tablet, described accessory package
Include one or more in following adjuvant: starch, lactose, pregelatinized Starch, microcrystalline Cellulose, refined honey etc.；Or it is above-mentioned thick
Cream is further dried, and pulverizes, makes pill, tablet or capsule.
5. the preparation method of the pharmaceutical composition described in claim 1: take Rhizoma Curcumae Longae, Fructus Crataegi, Fructus Crataegi, Fructus Lycii, adds 2-5 times of 60-90%
Alcohol heating reflux 1-2 hour, reflux, extract, 1-2 time, to filter, filtrate is condensed into thick paste；Above-mentioned thick paste adds adjuvant,
Making pill or tablet, described adjuvant includes one or more in following adjuvant: starch, lactose, pregelatinized Starch, micro-
Crystalline cellulose, refined honey etc.；Or above-mentioned thick paste is further dried, pulverizes, make pill, tablet or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510353665.5A CN106310108A (en) | 2015-06-24 | 2015-06-24 | Medicinal composition for treating fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510353665.5A CN106310108A (en) | 2015-06-24 | 2015-06-24 | Medicinal composition for treating fatty liver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106310108A true CN106310108A (en) | 2017-01-11 |
Family
ID=57729354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510353665.5A Pending CN106310108A (en) | 2015-06-24 | 2015-06-24 | Medicinal composition for treating fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106310108A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111166847A (en) * | 2019-12-23 | 2020-05-19 | 成都锦华药业有限责任公司 | Pharmaceutical composition containing turmeric, tablet thereof and preparation method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1724018A (en) * | 2005-07-13 | 2006-01-25 | 张惠云 | 'Wudan Xinggan' granular for treating fatty liver, and its prepn. method |
| CN101612362A (en) * | 2009-07-29 | 2009-12-30 | 湖南福湘生物技术有限公司 | A kind of blood lipid regulation, control cardiovascular and cerebrovascular disease compound preparation and preparation method thereof |
| CN102225120A (en) * | 2011-06-16 | 2011-10-26 | 安徽安科生物工程（集团）股份有限公司 | Medicine for treating fatty liver and preparation method thereof |
-
2015
- 2015-06-24 CN CN201510353665.5A patent/CN106310108A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1724018A (en) * | 2005-07-13 | 2006-01-25 | 张惠云 | 'Wudan Xinggan' granular for treating fatty liver, and its prepn. method |
| CN101612362A (en) * | 2009-07-29 | 2009-12-30 | 湖南福湘生物技术有限公司 | A kind of blood lipid regulation, control cardiovascular and cerebrovascular disease compound preparation and preparation method thereof |
| CN102225120A (en) * | 2011-06-16 | 2011-10-26 | 安徽安科生物工程（集团）股份有限公司 | Medicine for treating fatty liver and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 孙中朝等: "山楂的临床应用", 《中国民间疗法》 * |
| 毕焕春: "《保健药膳精要》", 30 September 2005, 江西科学技术出版社 * |
| 魏雅君等: "《肝脏保卫战》", 31 December 2014, 天津科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111166847A (en) * | 2019-12-23 | 2020-05-19 | 成都锦华药业有限责任公司 | Pharmaceutical composition containing turmeric, tablet thereof and preparation method |
| CN111166847B (en) * | 2019-12-23 | 2021-12-31 | 成都锦华药业有限责任公司 | Pharmaceutical composition containing turmeric, tablet thereof and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102727686B (en) | Traditional Chinese medicine composition for treating fatty liver | |
| CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
| CN104042802A (en) | Traditional Chinese medicine composition capable of treating fatty liver | |
| CN103933487A (en) | Compound traditional Chinese medicament for treating depression | |
| CN106376820A (en) | Solid drink for dispelling stomach cold and protecting gastric mucosa and preparation method thereof | |
| CN101933973B (en) | Medicament composition for preventing and treating liver damage | |
| CN101172155A (en) | Novel dosage forms of pulse-activating gallbladder warming soup and method of preparing the same | |
| CN103463409B (en) | Traditional Chinese medicine formula for treating heart qi deficiency | |
| CN102846879B (en) | Composition for depressing blood fat | |
| CN106309719A (en) | Medicinal composition for treating fatty livers | |
| CN105770579A (en) | Medicinal and edible homologous traditional Chinese medicine composition with liver-protecting effect | |
| CN104840871A (en) | Traditional Chinese medicine for treating alcoholic liver injury | |
| CN106310108A (en) | Medicinal composition for treating fatty liver | |
| CN102671056B (en) | Chinese medicinal composition for treating hepatitis and preparation method thereof | |
| CN103877323B (en) | Medicinal composition for treating non-alcoholic fatty liver disease | |
| CN104435772A (en) | Hawthorn-containing pharmaceutical composition for reducing blood fat | |
| CN103830337A (en) | Chinese medicinal composition for treating chronic alcoholic toxic liver disease | |
| CN114848764B (en) | Traditional Chinese medicine compound composition for preventing and treating liver injury and preparation method and application thereof | |
| CN103028028B (en) | Traditional Chinese medicine agent for treating primary hepatic carcinoma | |
| CN102462776A (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method and application thereof | |
| CN115944700A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN114712458A (en) | Pharmaceutical composition for treating vascular aging caused by hypertension and preparation method and application thereof | |
| CN104667001A (en) | Traditional Chinese medicine composition for treating stomach cancer | |
| CN104435205A (en) | Salvia-miltiorrhiza-containing pharmaceutical composition for reducing blood fat | |
| CN115120634A (en) | Traditional Chinese medicine compound preparation for preventing and treating alcoholic liver injury and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170111 |